Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Administration of scAAV9.CLN8 shows promise for treating CLN8-driven Batten disease

May 21, 2020

Janssen Pharmaceutica discloses SGLT2 inhibitors

May 21, 2020

Topline phase I data and interim phase I/II results presented for Trappsol Cyclo in NPC1

May 21, 2020

Janssen discovers novel potent EP inhibitors

May 19, 2020

Daiichi Sankyo, Sanford Burnham Prebys patent AP-TNAP inhibitors

May 15, 2020

Novadip reports interim data from phase I/II bone non-union study of NVD-003

May 15, 2020

Copper escort alleviates Menkes disease

May 14, 2020

miR-802 overexpression links obesity with impaired insulin transcription and secretion

May 13, 2020

Boehringer Ingelheim studies BI-456906 for type 2 diabetes in new phase II trial

May 12, 2020

CPU-025 demonstrates promising efficacy in mouse model of diabetes

May 12, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...